Abstract
Introduction

Hepatocyte growth factor (HGF), located chromosome 7q21.1, is also known as interleukin (IL)32b, scatter factor, hepatopoietin A, lung fibroblast-derived mitogen or fibroblast-derived tumour cytotoxic factor, mainly from epithelial origin cells. HGF binds to its receptor c-Met, acts as a multi-functional cytokine and regulates cell growth, motility and morphogenesis by activating a tyrosine kinase signalling cascade. The extracellular domain of c-Met comprises a large seven-bladed fl-propeller (Sema domain), a small cysteine rich domain and four immunoglobulin-like domains (Ig1-Ig4), of which the c-Met Sema and cysteine rich domains bind one domain of HGF
. HGF is secreted as a single inactive polypeptide and belongs to the plasminogen subfamily of S1 peptidases without the detectable protease activity [2] . It is cleaved by serine proteases into a 69-kD ␣-chain and 34-kD ␤-chain and becomes an active, heterodimeric molecule with the disulfide bond between the ␣ and ␤ chains. [6] .
The activation of the HGF/c-Met signal pathway stimulates mitogenesis, cell motility and matrix invasion. It may play a central role in angiogenesis, tumorogenesis and tissue regeneration. The present paper is to overview the potential role of the HGF/c-Met signal pathway in the development and metastasis of lung cancer, divert inhibitions of the HGF/c-Met signal, mechanisms of HGF/c-Met involvement in the metastasis by stimulating the production of vascular endothelial growth factor (VEGF) and activating the matrix metalloprotease (MMP), and possibility to be used as an independent or combining therapeutic target.
Does HGF/c-
The effect of NK4 treatment is highly dependent upon the deliveries of NK4 and the intratumoural adeno-associated virus-NK4 administration had the highest therapeutic response [7] . [14] . The CCL3-CCR5 axis signal was suggested to regulate HGF expression to accelerate neovascularization and subsequent metastasis formation probably through the production of VEGF [15] .
Does HGF/c-Met regulate VEGF production?
The activation of the HGF/Met signal has been shown to induce the development and angiogenesis of lung cancer, probably by stimulating the production of VEGF. The adaptor protein Shc was suggested as the proximal signalling proteins responsible for c-Met-induced VEGF expression, since c-Met failed to induce VEGF production in the Shc-deficient condition [16] .
VEGF could induce Shc recruitment to the kinases using mutants of the /ErbB2 receptor tyrosine kinase (RTK), where the mutant-bound Shc induced VEGF production. Shc was essential for the induction of VEGF production by the c-Met/HGF RTK oncoprotein and serum-derived growth factors. It implies that Shc acts as a critical angiogenic switch for VEGF production downstream from the c-Met and ErbB2 RTKs. Experimental findings demonstrated that c-Met was involved in tumorigenesis and liver metastasis by regulating the Src activation, since the down-regulation of c-Met
could reduce Src activity and activation of ERK1/2 and Akt, followed by a decreased VEGF production, tumour size and incidence, and vessel formation in tumours [17] . The inhibition of Src could reduce basal VEGF production, proliferation, migration and anchorage-independent growth, which could be rescued by [19] . Intrapulmonary levels of MMP-9 and HGF were found simultaneously higher during cancer metastasis to the lung [4] [24] . [27] , which was (Fig. 1) . It was proposed that c-Met might activate the EGFR agonist TGF through tumour suppressor phosphatase and tensin homolog [33] .
HGF. Such dose-dependent inhibitory effects on Src also reduced HGF-induced migration of tumours rather than HGF-induced anchorage-independent growth.
Does HGF/c-Met interact with MMPs?
HGF binds and activates c-Met through an autocrine signalling and an essential transcription factor for angiogenesis, ets-1, stimulating the matrix-degrading pathway such as the production of MMP-1 [18]. Growth factors secreted by either host or tumour cells play a major role in cell progression, by stimulating cell division and migration and modulating MMP production which are involved in the process of the invasion and metastasis. Growth factors could up-regulate the expression and activity of MMP-9 and MMP-2 in NSCLC cells where HGF and epidermal growth factor (EGF) could stimulate the conversion of MMP-9 from a latent to an active form
Does HGF/c-Met play a synergetic role?
The c-Met and epidermal growth factor receptor (EGFR) are potential targets of combination therapy for the cancer due to a wide expression on cancer cells during the development and progression of cancer. EGFR inhibitor has been used as a target therapy for NSCLC, of which about 80% highly expressed c-Met [8]. Coimmunoprecipitates of c-Met and EGFR were seen in protein extracts from tumour cells rather than normal cells [26]. It found that autocrine TGFa-activated EGFR caused phosphorylation of c-Met. Cross-talk between the TGFa/EGFR and the HGF/c-Met pathways might induce mitogenic or motogenic signal amplification and cell growth in the unidirectional way (Fig. 1). In the interaction between those two signalling pathways c-Met activation may initiate the transcription-dependent EGFR activation to carry out HGF-induced cell proliferation and motility
proposed to be EGFR dependent and/or through amphiregulin and heparin-binding EGF-like growth factor [28, 29]. The mechanism by which HGF induced migration of human lung cancer cells was proposed to be that Akt phosphorylation of HGF signalling inhibited the activity of phosphoinositide 3-kinase (PI3K), without affecting phosphorylation of Met and ERK [30]. Furthermore, it was demonstrated that HGF could induce EGFR inhibitor resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the PI3K/Akt signalling pathway via phosphorylation of c-Met [31]. The inhibition of c-Met by siRNA rather than EGFR or ErbB3 could reverse HGF-induced EGFR inhibitor resistance and phosphorylation of Akt. In lung cancer patients with intrinsic or acquired resistance to EGFR inhibitor, the immunoreactivity for HGF became stronger in cancer cells harbouring EGFR-activating mutations but no T790M mutation or MET amplification, a novel mechanism of EGFR inhibitor resistance and a considerable strategy for more successful treatment with EGFR inhibitors. However, the role of TGFa/EGFR-induced secondary phosphorylation of c-Met in the EGFR-dependent tumour growth remains questionable, since only a very small fraction of c-Met is phosphorylated by TGFa [26]. Recently, Gao et al. applied the global phosphoproteomic method to identify phosphotyrosine signalling downstream of EGFR and c-Met [32]. Amplified c-Met drives the activity of EGFR family members and mutated and amplified EGFR can also drive c-Met activity. When comparing the signalling networks in EGFR-dependent and c-Met-dependent cells, about 50 proteins were considered as the key factors to participate in pathways and mediate the response to drugs [32]. TGFa/EGFR signal was proposed to activate the phophorylation of c-Met, transcription factor ERK1, cytoskeletal reorganization factor Eps8 and adhesion factor CTNNB, while HGF/c-Met could activate the phosphorylation of endocytotic factor ANXA1, adaptor protein Gab1 as well as adhesion factors CTNNB and SHP2. Both TGFa/EGFR and HGF/c-Met signal pathways can directly activate CTNNB and indirectly activate the transcription factor Atk through the binding with HER3 or Gab1
In the cross-talk between TGFa/EGFR and HGF/c-Met signal pathways, the TGFa/EGFR signal pathway seems to play more dominate role and gain more scientific attention, most likely because the number of direct binding and indirect interaction factors of EGFR is more than c-Met [33] . There are about five to six more direct binding proteins with EGFR, e.g. adhesion protein SHP2, transcription factors STAT5 and 6, proliferation factor PLCG1, adaptor factor MIG6 and Gab1, as shown in Fig. 2 [34] . For [35] . c-MET signalling may play a key role in lung cancer oncogenic signalling and interface with EGFR, which may be an alternative co-therapy for EGFRI resistance NSCLC (Fig. 3) . c-Met amplification occurred independently of EGFRT790M mutations, indicating that c-Met may be a clinically relevant therapeutic target for some patients with acquired resistance to EGFR inhibitors [36] . [37] . The [40] .
. However, results from the study on the signalling networks between oncogenic EGFR and c-Met indicate that HGF/c-Met might have more indirect interaction with EGFR. NSCLC cell lines with the expression of both c-Met and EGFR (e.g. A549, H1838, H2170, SW900, SW1573, H358, SKLU-1 and H1993) had different sensibilities and responses to their ligands and inhibitors, associated with combining doses, rationales and durations
Experimental results demonstrated that both Met and EGFR were expressed in the EGFRI-resistant lung cancer cell line H1975 (L858R/T790M-mutant EGFR) and c-Met signalling had EGFRinhibitor-resistant role in lung cancer
HGF was found to suppress apoptosis-inducing factor expression and increase resistance of non-specific chemotherapy drugs for NSCLC, e.g. cisplatin, through c-met and its downstream effector, focal adhesion kinase [41] . Flavonoids (apigenin) could inhibit HGF-induced cancer cell motility, scattering, migration and invasion in a dose-dependent manner through down-regulation of Akt phosphorylation rather than c-Met, ERK and JNK phosphorylation [42] . Such non-specific compounds inhibited the HGF-induced clustering and function of ␤4 integrin at actin-rich adhesive site and lamellipodia, including cell-matrix adhesion and cell-endothelial cells adhesion through PI3K-dependent manner.
In conclusion, there is growing evidence that the HGF/c-Met signal play an important role in the development of NSCLC, Fig. 3 
